A significantly lower survival rate was found in NSCLC with STK11 and KEAP1 mutations among KRAS (Kirsten rat sarcoma virus)-mutated, but not KRAS wild-type patients, treated with immunotherapy [19]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.